Q-omics provides the consensus-scored LRRC72 profile across patient tissues and cancer cell-line models. LRRC72 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LRRC72 is differentially expressed in 3, with the highest sampling consensus in KICH. Additionally, LRRC72 RNA expression shows 7,552 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, KICH, and TGCT as cancer lineages where LRRC72 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC72 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC72 survival associations across molecular data types. LRRC72 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC72 RNA expression–survival associations across cancer types. High LRRC72 expression shows unfavorable associations in LIHC, KIRC, BLCA, SKCM, ESCA and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LRRC72 RNA expression.
This table summarizes LRRC72 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC72. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC72 shows lower tumor expression in KICH and COAD and higher tumor expression in HNSC. The KICH box plot shows higher LRRC72 RNA expression in normal versus tumor tissue (log2 FC = −0.019, t-test p = .012).
This table shows molecular features associated with LRRC72 in patient tissues and cancer cell lines. In patient samples, LRRC72 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC72 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
